A5041940487- Microscopic Colitis
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Inflammatory Bowel Disease
- Clinical Nutrition and Gastroenterology
- Esophageal and GI Pathology
- Colorectal Cancer Surgical Treatments
- Gastrointestinal Bleeding Diagnosis and Treatment
- Colorectal Cancer Screening and Detection
- Gastroesophageal reflux and treatments
- Eosinophilic Esophagitis
- Colorectal and Anal Carcinomas
- Health Systems, Economic Evaluations, Quality of Life
- Central Venous Catheters and Hemodialysis
- Nutrition and Health in Aging
- Cancer Treatment and Pharmacology
- Dysphagia Assessment and Management
- Neuroendocrine Tumor Research Advances
- Gastrointestinal Tumor Research and Treatment
- Helicobacter pylori-related gastroenterology studies
- Diverticular Disease and Complications
- Antioxidants, Aging, Portulaca oleracea
- Health Promotion and Cardiovascular Prevention
- Potassium and Related Disorders
The University of Texas MD Anderson Cancer Center
2018-2025
Hospital Alemão Oswaldo Cruz
2024
Beneficência Portuguesa de São Paulo
2024
West Virginia School of Osteopathic Medicine
2022
West Virginia University
2022
Leiden University
2021
Erasmus MC Cancer Institute
2021
Baptist Cancer Center
2018
Massachusetts General Hospital
2018
University of Colorado Anschutz Medical Campus
2018
Diarrhea and colitis are the second most common immune checkpoint inhibitor (ICPI)-induced adverse events. However, a comprehensive characterization of endoscopic histologic features ICPI-induced diarrhea is lacking. Therefore, we aimed to describe gastrointestinal toxicities assess their association with patients’ clinical characteristics outcomes. We retrospectively reviewed records 53 patients ICPI-related diarrhea/colitis between 2011 2017. collected data on demographics, grade,...
<h3>Background</h3> Immune-mediated diarrhea and colitis (IMDC) can limit immune checkpoint inhibitors (ICIs) treatment, which is efficacious for advanced malignancies. Steroids infliximab are commonly used to treat it. These agents induce systemic immunosuppression, with its associated morbidity. We assessed clinical outcomes of vedolizumab as an alternative treatment IMDC. <h3>Methods</h3> analyzed a retrospective case series adults who had IMDC refractory steroids and/or received from...
Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC) recommend steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) refractory cases. We aimed to compare the efficacy of these two SITs their impact on cancer outcomes.We performed a two-center, retrospective observational cohort study patients with IMDC who received following from 2016 2020. Patients' demographic, clinical, overall survival data were...
Abstract Background Microscopic colitis (MC) has been described as 1 pattern of injury in immune checkpoint inhibitor (ICPI)–induced colitis. The main objective this study was to characterize ICPI-induced MC by exploring the differences risk factors, treatments, endoscopic features, and clinical outcomes between cancer noncancer patients with without exposure ICPIs. Methods A retrospective chart review conducted among diagnosed from our institutional pathology database January 2012 2018....
Background: Immune checkpoint inhibitors (ICIs) have demonstrated effectiveness in treating many malignancies. Gastrointestinal (GI) adverse events are commonly reported; however, few reports describe upper GI tract toxic effects. We aimed to clinical features of injury related ICI.Methods: studied consecutive patients who received ICIs between April 2011 and March 2018 developed symptoms requiring esophagogastroduodenoscopy (EGD).Results: Sixty ICI initiation 6 months after the last...
BACKGROUND: A study was performed to measure the quality of life patients receiving home parenteral nutrition (HPN). Quality is an important determinant effectiveness health technologies, but it has rarely been assessed in HPN. AIMS: To and highlight any moderating factors. PATIENTS AND METHODS: measured using two validated instruments (SF 36 EuroQol) 51 with intestinal failure. All had benign disease, commonest being Crohn9s disease (n = 35). RESULTS: HPN patient scores were worse for six...
An economic evaluation of home parenteral nutrition (HPN) for intestinal failure is presented. The cost-utility HPN and factors affecting the ratio were examined to determine whether current practice most efficient way treating failure. Quality-adjusted life-years (QALYs) gained measured using a validated health status questionnaire. cost patient with was calculated, marginal per QALY ratios obtained. an average approximately 68,975 pounds, but value patients over 55 years age about 126,865...
Objective To measure quality of life (QoL), using validated health status instruments, patients with functioning IPAA for CUC. Patients and methods Between 1986 1997, a total 77 had an IPAA. Thirteen were excluded [6 excised, 3 awaiting ileostomy closure, 2 lost to follow up, serious unrelated illnesses]. Postal survey SF36 EuroQol questionnaires. Age, sex, year pouch construction stool frequency documented. Results Fifty‐six (87.5%) replied. Male:female ratio; 3:2. Median age; 34 years...
Home parenteral nutrition (HPN) is used to treat intestinal failure. A minority of HPN patients are dependent on opiates and benzodiazepines control pain anxiety. The aim this study was determine what effects such drug dependence had patient outcomes.Ten were prospectively compared with 10 well-matched, nondependent for the same 12-month period. Episodes line sepsis other complications documented cost treatment estimated. Health status measured using SF36 EuroQol instruments.The group...
Background: Chimeric antigen receptor T-cell (CART) therapy can significantly improve outcomes for patients with certain hematologic malignancies. The most notable drawbacks of CART are cytokine release syndrome and CART-related encephalopathy syndrome. Gastrointestinal adverse events (GI-AEs) have not yet been reported in association CART. Herein, we describe the incidence clinical features GI-AEs observed after Materials Methods: We report a case series malignancies who received CART,...
Although immune checkpoint inhibitors (ICIs) have provided practice-changing outcomes in treating many cancers, ICI-related gastrointestinal toxicity can limit their use. Upper is not common nor as well described lower toxicity. We aimed to characterize the clinical presentation, endoscopic and histologic features, treatment response, of esophagitis.We retrospectively studied patients at The University Texas MD Anderson Cancer Center whom esophagitis developed after receiving ICIs from June...
INTRODUCTION: Immune-mediated diarrhea and colitis (IMDC) may limit immune checkpoint inhibitors (ICIs) treatment. Current treatment for IMDC uses steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT = infliximab or vedolizumab add-on) if steroid refractory. We aimed to compare the efficacy of SIT on impact cancer outcomes. METHODS: performed a retrospective cohort study patients with who received following from 6/2016 3/2020. Patient’s demographics, clinical...